Shares of Aldeyra Therapeutics ALDX plunged 70.7% on Tuesday after the company announced receiving a Complete Response Letter ...

In its complete response letter, the FDA said Aldeyra had failed to demonstrate reproxalap’s efficacy in adequate and ...

Previously, the Company had received CRLs in November 2023 and April 2025 due to insufficient evidence in addressing the ...

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative ...

After delaying its review, the FDA has rejected Aldeyra Therapeutics’ experimental dry eye disease treatment for the third ...

Researchers have predicted that cases of glaucoma, a common eye condition that can lead to blindness if not treated, are expected to increase around the world in the coming years. There is a ...

Thyroid eye disease is a chronic autoimmune disorder that inflames tissues behind the eye. Swelling can cause dry, irritated eyes, bulging, light sensitivity, and double vision. Thyroid eye disease ...

Nearly a quarter of patients with hidradenitis suppurativa (HS) experienced concomitant eye disease, and among those who did, nearly one third had a partial response with treatment, results from a ...

Dry eye has emerged as an early warning sign of autoimmune disease, appearing roughly three years before many patients ...

Cycle for Sight 2026 is underway following a kickoff event at Princeton Club West in Madison. The campaign asks participants ...

A new study demonstrates the effectiveness of a widely-used eye injection to manage the previously untreatable rare condition, hypotony, in a project by clinical researchers at UCL and Moorfields Eye ...